JP2017536363A5 - - Google Patents

Download PDF

Info

Publication number
JP2017536363A5
JP2017536363A5 JP2017526853A JP2017526853A JP2017536363A5 JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5 JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017526853 A JP2017526853 A JP 2017526853A JP 2017536363 A5 JP2017536363 A5 JP 2017536363A5
Authority
JP
Japan
Prior art keywords
composition
disease
drug
pharmaceutical combination
fibrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536363A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060878 external-priority patent/WO2016081365A1/en
Publication of JP2017536363A publication Critical patent/JP2017536363A/ja
Publication of JP2017536363A5 publication Critical patent/JP2017536363A5/ja
Pending legal-status Critical Current

Links

JP2017526853A 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法 Pending JP2017536363A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081696P 2014-11-19 2014-11-19
US62/081,696 2014-11-19
PCT/US2015/060878 WO2016081365A1 (en) 2014-11-19 2015-11-16 Compositions and methods for treating lysosomal disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019232644A Division JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2017536363A JP2017536363A (ja) 2017-12-07
JP2017536363A5 true JP2017536363A5 (https=) 2018-10-18

Family

ID=56014423

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017526853A Pending JP2017536363A (ja) 2014-11-19 2015-11-16 リソソーム蓄積症治療のための組成物及び方法
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019232644A Pending JP2020100621A (ja) 2014-11-19 2019-12-24 リソソーム蓄積症治療のための組成物及び方法
JP2021063971A Active JP7752958B2 (ja) 2014-11-19 2021-04-05 リソソーム蓄積症治療のための組成物及び方法
JP2021153206A Withdrawn JP2022003060A (ja) 2014-11-19 2021-09-21 リソソーム蓄積症治療のための組成物及び方法

Country Status (9)

Country Link
US (3) US20170354666A1 (https=)
EP (2) EP3220906B1 (https=)
JP (4) JP2017536363A (https=)
KR (1) KR20170083146A (https=)
CN (1) CN107205976A (https=)
AU (1) AU2015350223B2 (https=)
CA (2) CA2967066C (https=)
ES (1) ES2914085T3 (https=)
WO (1) WO2016081365A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509030TA (en) 2013-05-07 2015-11-27 Bio Blast Pharma Ltd Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose
CN107205976A (zh) * 2014-11-19 2017-09-26 拉什大学医学中心 用于治疗溶酶体病症的组合物和方法
US11008277B2 (en) * 2016-06-13 2021-05-18 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US10815184B2 (en) * 2016-06-13 2020-10-27 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
CN110167545A (zh) * 2016-12-29 2019-08-23 拉什大学医学中心 吉非罗齐对晚期婴儿型神经元蜡样质脂褐质沉积症患者寿命的增加和自发活动的改善
KR102572663B1 (ko) * 2017-02-08 2023-09-01 노파르티스 아게 Fgf21 모방 항체 및 이의 용도
US12091706B2 (en) * 2018-01-30 2024-09-17 Rush University Medical Center Sequential staining for multiplex analyses of tissues and cells
WO2019156252A1 (ja) * 2018-02-06 2019-08-15 国立大学法人京都大学 ライソゾーム病の予防及び治療剤
WO2019226786A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
CA3118918A1 (en) 2018-11-05 2020-05-14 Rush University Medical Center Nasal delivery of low-dose aspirin for the treatment of neurodegenerative and lysosomal storage diseases
BR112021012950A2 (pt) * 2019-01-03 2021-09-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Métodos e materiais para aumentar os níveis de polipeptídeo do fator de transcrição eb
WO2020176432A1 (en) * 2019-02-25 2020-09-03 Rush University Medical Center Compositions including cinnamic acid and methods of use thereof
CA3132379A1 (en) * 2019-03-22 2020-10-01 Rush University Medical Center Combination of nasal gene delivery and oral cinnamic acid, oleamide or gemfibrozil for lysosomal storage disorders
US20220313722A1 (en) * 2019-09-09 2022-10-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of restoring lysosomal function of retinal pigment epithelial cells by activation of tfeb
IL291799A (en) * 2019-10-01 2022-06-01 Seelos Therapeutics Inc Trehalose formulations and uses thereof
EP4281118A4 (en) * 2021-01-20 2025-01-01 Rush University Medical Center Improved treatment for globoid cell leukodsytrophy or krabbe disease
CA3241282A1 (en) * 2021-12-16 2023-06-22 Kalipada PAHAN Benzoic acid salts for treatment of nervous system injuries and disorders
JP2025503041A (ja) * 2022-01-20 2025-01-30 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経障害および精神障害におけるリソソーム機能障害
US12042476B2 (en) * 2022-02-04 2024-07-23 Mcmaster University Methods for the treatment of lysosomal storage diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE320803T1 (de) 1998-01-28 2006-04-15 Warner Lambert Co Verfahren zur behandlung von alzheimerschen krankheit
AU2001233299A1 (en) 2000-02-04 2001-08-14 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
EP1732605B1 (en) * 2004-03-29 2019-05-08 Wyeth LLC Multi-vitamin and mineral nutritional supplements
US20060135612A1 (en) * 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
ES2246737B1 (es) * 2005-06-09 2006-12-01 Jose Juan Rodriguez Jerez "composicion farmaceutica que comprende lisina y usos correspondientes".
JP2009084155A (ja) * 2006-01-16 2009-04-23 Kanazawa Univ レビー小体病治療薬及びレビー小体病予防薬
US20070225360A1 (en) 2006-03-22 2007-09-27 L'oreal Anti-aging composition containing phloretin
GB0718824D0 (en) * 2007-09-26 2007-11-07 Univ Ramot Methods of treating lysosomal storage disorders
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
US9388414B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
US9388413B2 (en) * 2008-10-08 2016-07-12 Trustees Of Dartmouth College Method for selectively inhibiting ACAT1 in the treatment of neurodegenerative diseases
JP2010106001A (ja) 2008-10-31 2010-05-13 Theravalues Corp Ｐｐａｒ活性化剤
EP2218458A1 (en) * 2009-02-13 2010-08-18 Fondazione Telethon Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof
SI2995306T1 (sl) * 2009-10-19 2019-04-30 Amicus Therapeutics, Inc. Novi sestavki za preprečevanje in/ali zdravljenje motenj lizosomskega shranjevanja
CN103458970A (zh) * 2011-03-07 2013-12-18 泰莱托恩基金会 Tfeb磷酸化抑制剂及其应用
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
PL399467A1 (pl) * 2012-06-08 2013-12-09 3G Therapeutics Inc. Zastosowanie genisteiny do obnizania poziomu zwiazków organicznych spichrzanych w komórkach w leczeniu i/lub zapobieganiu lizosomalnych chorób spichrzeniowych (LChS)
WO2014089449A1 (en) * 2012-12-07 2014-06-12 Rush University Nedical Center Composition and method for treating neuronal ceroid lipofuscinosis
CN107205976A (zh) * 2014-11-19 2017-09-26 拉什大学医学中心 用于治疗溶酶体病症的组合物和方法

Similar Documents

Publication Publication Date Title
JP2017536363A5 (https=)
Pena-Altamira et al. Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation
Lazo-Gómez et al. Histone deacetylases and their role in motor neuron degeneration
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112015010477A2 (pt) combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
NZ743714A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2015503593A5 (https=)
Dubey et al. Recent studies on cellular and molecular mechanisms in Alzheimer’s disease: focus on epigenetic factors and histone deacetylase
Batiha et al. Potential role of lipoxin in the management of COVID-19: a narrative review
WO2012030160A3 (en) Quinoline or quinazoline derivatives with apoptosis inducing activity on cells
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12012502447A1 (en) Tetrahydrocarboline derivative
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2849738A4 (en) HIGH-POWDER PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF LUNG DISEASES
JP2016518338A5 (https=)
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
Oliveira et al. HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015)
HRP20210361T1 (hr) Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja
BR112014015578A8 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
Zhang et al. Advancing histone deacetylase 6 (HDAC6) as a promising therapeutic target for Alzheimer’s disease: from molecular insights to clinical prospects
Khan et al. Epigenetic Regulation Mediating Immunopathology in Parkinson’s Disease
Hur Recent Guidelines on the Management of Blood Cholesterol: 2013 ACC/AHA Guidelines and 2014 NICE Draft Guidelines
Maes et al. The DNA methyltransferase inhibitor decitabine induces DNA damage, cell cycle arrest and apoptosis in multiple myeloma
Rudan The role of rosuvastatin in primary and secondary prevention of cardiovascular events and influence on patient compliance